cmt2d neuropathy linked neomorphic binding activity glycyl-trna synthetase 
selective neuronal loss hallmark neurodegenerative diseases counterintuitively often caused mutations widely expressed genes charcot-marie-tooth cmt diseases common hereditary peripheral neuropathies effective therapies23 subtype diseases cmt type 2d cmt2d-is caused dominant mutations gars encoding ubiquitously expressed enzyme glycyl-transfer rna trna synthetase glyrs despite broad requirement glyrs protein biosynthesis cells mutations gene cause selective degeneration peripheral axons leading deficits distal motor function4 mutations glyrs glyrscmt2d linked motor neuron vulnerability remained elusive report glyrscmt2d acquires neomorphic binding activity directly antagonizes essential signalling pathway motor neuron survival find cmt2d mutations alter conformation glyrs enabling glyrscmt2d bind neuropilin nrpl receptor aberrant interaction competitively interferes binding cognate ligand vascular endothelial growth factor vegf nrpl genetic reduction nrpl mice worsens cmt2d symptoms whereas enhanced expression vegf improves motor function findings link selective pathology cmt2d neomorphic binding activity glyrscmt2d antagonizes vegf-nrp1 interaction indicate vegf-nrp1 signalling axis actionable target treating cmt2d 
